#USA #San Francisco #Securities Fraud #class action lawsuit #PROCEPT BioRobotics

PROCEPT BioRobotics Investors Alerted to Class Action Lawsuit

Investors in PROCEPT BioRobotics Corporation (NASDAQ: PRCT) have been alerted by Hagens Berman Sobol Shapiro LLP regarding the potential to lead a class action lawsuit. This comes on the heels of troubling revelations concerning the company’s sales practices and overall financial performance.

The roots of the legal action stem from an alarming trend marked by unexpected underperformance in unit sales of the company’s handpieces, crucial components of its Aquablation therapy for treating enlarged prostates. Over the course of the class period, which stretches from February 28, 2024, to February 25, 2026, investors were purportedly misled by PROCEPT about both the extent of its sales and the health of its business.

Background of the Case

On numerous occasions, PROCEPT publicly touted its sales growth, building investor confidence. However, this confidence was undermined when it was discovered that the company was employing an extensive discount program that encouraged bulk orders beyond customers' actual demands, leading to inflated sales figures. This practice pulled sales into earlier quarters, giving a misleading impression of stability and growth.

The situation worsened as investors uncovered spikes in excess inventory levels, suggesting a market that was not as robust as previously indicated. By the time PROCEPT released its Q2 2025 financial results, investors were hit with the reality of deteriorating handpiece sales numbers that fell significantly below projections.

Impact on Shareholders

The significant drop in share price following the quarterly disclosures sent shockwaves through the investor community. For instance, following the August 6, 2025 announcement that PROCEPT's handpiece sales had unexpectedly declined, the stock price saw a notable decrease. Further disappointing announcements in November and February added to the turmoil, leading to a total price decline of over 48% from earlier highs.

Key details from the financial reports included admissions from company management regarding customer inventory mismanagement. Specifically, amassed customer inventories exceeded 10,000 units, suggesting poor forecasting and inventory management practices.

Legal Implications

The possibly deceptive practices employed by PROCEPT raise serious questions about compliance with federal securities laws. Investors are now being encouraged to come forward if they have suffered substantial losses as a result of these developments. The leading attorneys of Hagens Berman, involved in the case, assert that transparency regarding the company’s operations and sales was grossly lacking, prompting the legal action.

Hagens Berman is actively seeking to compile a firm case to hold PROCEPT accountable, which could potentially result in financial compensation for affected investors. The law firm urges any shareholders with information or who have incurred losses to connect with their legal representatives.

In a landscape fraught with corporate accountability challenges, this case serves as a reminder of the importance of transparency in investor communication. Hagens Berman has a notable track record in handling complex securities lawsuits, having recovered over $2.9 billion for affected parties in previous cases, emphasizing their commitment to uphold the rights of investors.

Conclusion

For shareholders of PROCEPT BioRobotics, this lawsuit offers a channel to pursue justice for losses incurred due to misleading information and potentially fraudulent practices. Investors are advised to stay informed and engaged as the legal proceedings unfold. Those interested in assisting with the investigation can reach out to the firm through the provided contact details.

Hagens Berman continues to advocate for investors and promote accountability among corporations, continuing their mission to protect the financial well-being of the investing public.